Heron Therapeutics Inc (NASDAQ:HRTX) has a beta value of 1.78 and has seen 1.0 million shares traded in the last trading session. The HRTX stock price is -120.79% off its 52-week high price of $3.93 and 71.91% above the 52-week low of $0.50. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.53 million shares traded. The 3-month trading volume is 2.01 million shares.
The consensus among analysts is that Heron Therapeutics Inc (HRTX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Over the past 30 days, the shares of Heron Therapeutics Inc (NASDAQ:HRTX) have changed -16.04%. Short interest in the company has seen 30.64 million shares shorted with days to cover at 15.54.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 74.57% from current levels. The projected low price target is $5.0 while the price target rests at a high of $9.0. In that case, then, we find that the current price level is -405.62% off the targeted high while a plunge would see the stock gain -180.9% from current levels.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Figures show that Heron Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -37.32% over the past 6 months, with this year growth rate of 86.25%, compared to 18.30% for the industry. Revenue growth from the last financial year stood is estimated to be 16.80%.
3 analysts offering their estimates for the company have set an average revenue estimate of 36.93M for the current quarter. 3 have an estimated revenue figure of 40.73M for the next ending quarter. Year-ago sales stood 31.43M and 34.23M respectively for this quarter and the next, and analysts expect sales will grow by 17.50% for the current quarter and 16.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.01% over the past 5 years. Earnings growth for 2024 is a modest 84.30% while over the next 5 years, the company’s earnings are expected to increase by 47.50%.
HRTX Dividends
Heron Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Insiders own 0.69% of the company shares, while shares held by institutions stand at 86.76% with a share float percentage of 87.36%. Investors are also buoyed by the number of investors in a company, with Heron Therapeutics Inc having a total of 224.0 institutions that hold shares in the company. The top two institutional holders are RUBRIC CAPITAL MANAGEMENT LP with over 26.71 million shares worth more than $93.5 million. As of 2024-06-30, RUBRIC CAPITAL MANAGEMENT LP held 17.6678% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 8.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $30.16 million and represent 5.6984% of shares outstanding.
